Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. Arrowhead is currently investigating ARO-ANG3 in a Phase 1/2 clinical trial. 8,314,227, 9,051,570, and 9,303,260 related to unlocked nucleotide analogs ("UNA"). 8,084,599, 8,658,356, 8,691,786, 8,796,444, 8,809,515, and 9,518,262. The FDA may request additional information rather than accept an NDA for filing. A fee is incurred with each scientific advice procedure. The off-label promotion of pharmaceutical products is prohibited in the European Union. As a result, increasingly high barriers are being erected to the entry of new products. The SEC's Internet website address is http://www.sec.gov. Our technology licensed from various third parties may be subject to retained rights. We rely on outside sources for various components and processes for our products. There are a limited number of manufacturers that supply synthetic oligonucleotides. Such events could cause interruption of our operations and loss of intellectual property. It is possible that we have experienced an ownership change limitation. We are focused on technology related to new and improved pharmaceutical candidates.